Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/14/2008

ver

50% of the AIDS virus (HIV-1) protein components in order to stimulate

a broad anti-HIV immune response. The vaccines cannot cause AIDS

because they do not include complete virus. A Phase 1 human trial,

started in April 2006, evaluated the delivery of only 1/10th of the

full dosage and utilized the same vaccine regimen evaluated in the full

dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:
-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate

that they are quite safe and immunogenic following the delivery of

the four full-doses (two of each vaccine) used in the trial's

protocol.

-- The full-dose regimen of GeoVax vaccines continues to be well

tolerated without any type of reaction, mild or systemic, in the

majority of participants.

-- CD4 T-cell responses are high in both the low and full-dose regimens,

84% and 78% of participants.

-- CD8 T-cell responses are present in 42% of the full-dose recipients

and 33% of the 1/10th dose recipients.

-- Antibody responses to the envelope glycoprotein (Env) increased

following the fourth vaccination, and were present in 88% of the

full-dose participants.

-- Delivery of the fourth vaccination increased the frequency and

magnitude of the CD8 T-cell and Antibody responses.

-- During November 2007 through January 2008, GeoVax raised approximately

$3 million in equity capital through a series of privately negotiated

transactions with individual accredited investors and one institutional

investor. These funds, along with the funds received pursuant to the

NIH grant discussed above will be used to offset the Company's ongoing

research and development costs and
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
2. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
6. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
10. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
11. PLC Systems Reports Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , ... SRNE ;  Sorrento), an oncology company ... and Conkwest, Inc., a privately-held immuno-oncology company developing ... (NK) cell-line based therapy, announced today that the ... jointly develop next generation CAR-TNK™ (pronounced as "Car-Tank") ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... March 31 We may introduce the first,"A"- Implant novelty from Austria: ... - two-part system, - extraordinary stability, ... of most reliable Zirconium oxide, - Manufactured for your ... After 4 years of research and technical development, ...
... in new super pill ORLANDO, Fla. and DENVER, ... Board: CONX) announced today that its AspirinWorks Test ... Study (TIPS) to help determine patients, response to ... the effect of combinations of aspirin, statin and ...
Cached Medicine Technology:Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 2Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09 3
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey ... decade. They’ve treated over 40,000 patients while carrying out ... alternative to the Paramus area. , For 2015, the ... staff of top-notch board certified physicians: Christine Milosis MD, Sandra ... new doctors will work tirelessly to carry out The ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
(Date:12/20/2014)... The Twin Cities DI Day is recognized as the ... 250 financial professionals come together each year to hear ... motivated to protect their clients and to be inspired ... challenges of disability. , On September 23rd, 2014, financial ... attend The 13th Annual Twin Cities DI Day where ...
Breaking Medicine News(10 mins):Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3
... change and the story behind Antarctica’s icy ambience, is unraveled ... clue. ,An element pretty unheard of and extremely ... clue to the University of Florida geologists in estimating the ... have opened up. This has happened obviously millions of years ...
... is being prompted by the Drug Manufacturer, Wyeth to ... drugs to treat menopause.// The drugs are made as ... ,Following Wyeth's recommendation to the FDA, the agency ... these custom-made treatments, and have requested the agency not ...
... can explain why men and women experience pain differently ... certain pain-relief drugs, reveals a new study conducted by ... for Behavioral Neuroscience (CBN). ,Although the study ... that similar differences occur in humans as well. The ...
... report by the Food and Agriculture Organisation (FAO) of the ... species said that domestic and wild birds spread the bird ... since the start of the avian influenza crisis (the end ... the transmission of the virus in the natural setting. ...
... as a clean up drive legalisation of drugs is in ... drugs to addicts// to help clean up the Downtown Eastside ... Sullivan a donation by an anonymous donor of $500,000 to ... reason and goal behind this whole exercise would be to ...
... flu in Ethiopia has been dismissed by health officials, following ... for the presence of the H5N1 virus. ,Officials ... organized on Thursday that no outbreak of bird flu has ... in several parts of the country. ,All necessary ...
Cached Medicine News:Health News:Gender Difference In Pain Experience Explained By Brain Diversity 2
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: